Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019Veda N. Giri, Albert Dobi, Heather H. Cheng et al.|Journal of Clinical Oncology|2020Cited by 280
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced NeuropathyDaniel L. Hertz, Howard L. McLeod, Kouros Owzar et al.|Clinical Cancer Research|2016Cited by 57
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)Jai N. Patel, Howard L. McLeod, Chen Jiang et al.|Cancer|2014Cited by 35
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patientsJúlia C.F. Quintanilha, Federico Innocenti, Jin Wang et al.|British Journal of Cancer|2021Cited by 24
Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach.Susan F. Slovin, Howard I. Scher, P O Livingston et al.|PubMed|1996Cited by 19